Revvity (RVTY) announced a collaboration with Eli Lilly (LLY) that expands access to Lilly’s models by making Lilly TuneLab available through the Revvity Signals platform. The collaboration builds on Revvity’s recently introduced Signals Xynthetica offering.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVTY:
- Revvity price target raised to $112 from $108 at Evercore ISI
- OpenAI spoke to Revvity about licensing data, The Information reports
- Revvity price target raised to $107 from $102 at Wells Fargo
- BofA shakes up ratings in Biopharma Services with seven changes
- Revvity downgraded to Neutral from Buy at BofA